CX3CL1 and neoplasm: Furthermore, the addition of 1 ng or 10 ng of recombinant CX3CL1 (rCX3CL1) to a non-immunogenic dose of dying/dead cancer cells for prophylactic vaccination of mice significantly increased the tumour-free survival of mice and restored immunogenicity of dying cancer cells.